Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

Core Insights - Cardiff Oncology is focusing on the treatment landscape for first-line RAS-mutated metastatic colorectal cancer (mCRC) and the potential of its PLK1 inhibitor, onvansertib, to enhance patient outcomes when combined with standard therapies [2][3] Industry Context - March is recognized as national colorectal cancer awareness month, highlighting the importance of understanding prevention, detection, and treatment of colorectal cancers [3] - In 2025, over 154,000 patients in the U.S. were diagnosed with colorectal cancer, with nearly 53,000 fatalities, indicating a significant public health issue [3] - There has been limited progress in treating first-line RAS-mutated mCRC, revealing a substantial unmet medical need in this area [3]